Super Dominant Pathobiontic Bacteria in the Nasopharyngeal Microbiota Cause Secondary Bacterial Infection in COVID-19 Patients

The nasopharyngeal microbiota is composed of a variety of not only the true commensal bacterial species but also the two-face pathobionts, which are one a harmless commensal bacterial species and the other a highly invasive and deadly pathogen. In a previous study, we found that the diversity of nasopharyngeal microbiota was lost in severe influenza patients. ABSTRACT Coronavirus disease 2019 (COVID-19) is a respiratory infectious disease responsible for many infections worldwide. Differences in respiratory microbiota may correlate with disease severity. Samples were collected from 20 severe and 51 mild COVID-19 patients. High-throughput sequencing of the 16S rRNA gene was used to analyze the bacterial community composition of the upper and lower respiratory tracts. The indices of diversity were analyzed. When one genus accounted for >50% of reads from a sample, it was defined as a super dominant pathobiontic bacterial genus (SDPG). In the upper respiratory tract, uniformity indices were significantly higher in the mild group than in the severe group (P < 0.001). In the lower respiratory tract, uniformity indices, richness indices, and the abundance-based coverage estimator were significantly higher in the mild group than in the severe group (P < 0.001). In patients with severe COVID-19, SDPGs were detected in 40.7% of upper and 63.2% of lower respiratory tract samples. In patients with mild COVID-19, only 10.8% of upper and 8.5% of lower respiratory tract samples yielded SDPGs. SDPGs were present in both upper and lower tracts in seven patients (35.0%), among which six (30.0%) patients possessed the same SDPG in the upper and lower tracts. However, no patients with mild infections had an SDPG in both tracts. Staphylococcus, Corynebacterium, and Acinetobacter were the main SDPGs. The number of SDPGs identified differed significantly between patients with mild and severe COVID-19 (P < 0.001). SDPGs in nasopharyngeal microbiota cause secondary bacterial infection in COVID-19 patients and aggravate pneumonia. IMPORTANCE The nasopharyngeal microbiota is composed of a variety of not only the true commensal bacterial species but also the two-face pathobionts, which are one a harmless commensal bacterial species and the other a highly invasive and deadly pathogen. In a previous study, we found that the diversity of nasopharyngeal microbiota was lost in severe influenza patients. We named the genus that accounted for over 50% of microbiota abundance as super dominant pathobiontic genus, which could invade to cause severe pneumonia, leading to high fatality. Similar phenomena were found here for SARS-CoV-2 infection. The diversity of nasopharyngeal microbiota was lost in severe COVID-19 infection patients. SDPGs in nasopharyngeal microbiota were frequently detected in severe COVID-19 patients. Therefore, the SDPGs in nasopharynx microbiota might invade into low respiratory and be responsible for secondary bacterial pneumonia in patients with SARS-CoV-2 infection.

[1]  E. Sklan,et al.  Secondary bacterial infection in COVID-19 patients is a stronger predictor for death compared to influenza patients , 2021, Scientific Reports.

[2]  Tao Zhang,et al.  Temporal association between human upper respiratory and gut bacterial microbiomes during the course of COVID-19 in adults , 2021, Communications biology.

[3]  S. Rajagopala,et al.  SARS-CoV-2 infection and viral load are associated with the upper respiratory tract microbiome , 2021, Journal of Allergy and Clinical Immunology.

[4]  A. Koohpaei,et al.  Evaluation of bacterial co-infections of the respiratory tract in COVID-19 patients admitted to ICU , 2020, BMC Infectious Diseases.

[5]  H. Keyvani,et al.  Bacterial co‐infections with SARS‐CoV‐2 , 2020, IUBMB life.

[6]  T. Akande,et al.  COVID-19 pandemic: A global health burden , 2020, The Nigerian postgraduate medical journal.

[7]  G. Cooke,et al.  Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  J. Rello,et al.  Burden of Community-Acquired Pneumonia and Unmet Clinical Needs , 2020, Advances in Therapy.

[9]  G. Gao,et al.  A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.

[10]  Junrong Liang,et al.  Super-dominant pathobiontic bacteria in the nasopharyngeal microbiota as causative agents of secondary bacterial infection in influenza patients , 2020, Emerging microbes & infections.

[11]  A. Musani,et al.  Community-acquired Pneumonia and Hospital-acquired Pneumonia. , 2019, The Medical clinics of North America.

[12]  Chunling Xiao,et al.  Air pollution during the winter period and respiratory tract microbial imbalance in a healthy young population in Northeastern China. , 2019, Environmental pollution.

[13]  Yangfeng Wu,et al.  High-Level PM2.5/PM10 Exposure Is Associated With Alterations in the Human Pharyngeal Microbiota Composition , 2019, Front. Microbiol..

[14]  M. Hornef Pathogens, Commensal Symbionts, and Pathobionts: Discovery and Functional Effects on the Host. , 2015, ILAR journal.

[15]  Didier Raoult,et al.  Current and Past Strategies for Bacterial Culture in Clinical Microbiology , 2015, Clinical Microbiology Reviews.

[16]  Jun Yu,et al.  Human Pharyngeal Microbiome May Play A Protective Role in Respiratory Tract Infections , 2014, Genom. Proteom. Bioinform..

[17]  R. Murray,et al.  Community-Acquired Pneumonia Due to Pandemic A(H1N1)2009 Influenzavirus and Methicillin Resistant Staphylococcus aureus Co-Infection , 2010, PloS one.

[18]  Anthony S Fauci,et al.  Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. , 2008, The Journal of infectious diseases.

[19]  J. McCullers Insights into the Interaction between Influenza Virus and Pneumococcus , 2006, Clinical Microbiology Reviews.

[20]  D. Jones Influenza and meningococcal disease , 1994, The Lancet.

[21]  D. Jones,et al.  Influenza A and meningococcal disease , 1991, The Lancet.

[22]  Wilson Smith,et al.  A Virus obtained from influenza patients , 1933 .